§ 314.600. Scope.

151 words·~1 min read·/us/cfr/t21/s§ 314.600·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

This subpart applies to certain new drug products that have been studied for their safety and efficacy in ameliorating or preventing serious or life-threatening conditions caused by exposure to lethal or permanently disabling toxic biological, chemical, radiological, or nuclear substances. This subpart applies only to those new drug products for which: Definitive human efficacy studies cannot be conducted because it would be unethical to deliberately expose healthy human volunteers to a lethal or permanently disabling toxic biological, chemical, radiological, or nuclear substance; and field trials to study the product's effectiveness after an accidental or hostile exposure have not been feasible.

This subpart does not apply to products that can be approved based on efficacy standards described elsewhere in FDA's regulations (e.g., accelerated approval based on surrogate markers or clinical endpoints other than survival or irreversible morbidity), nor does it address the safety evaluation for the products to which it does apply.

Connections17 cite this

Cited by 17 sections · top 12

Citation graph

cites case law

§ 314.600

Scope.

Fed. Reg.×17

Cites 0Cited by 17 across 1 source